Genmab A/SGMABNASDAQ
Loading
Revenue Growth AcceleratingAccelerating
Percentile Rank95
3Y CAGR+179.0%
5Y CAGR+97.5%
Year-over-Year Change
Year-over-year revenue growth rate
3Y CAGR
+179.0%/yr
vs -8.6%/yr prior
5Y CAGR
+97.5%/yr
Recent acceleration
Acceleration
+187.5pp
Accelerating
Percentile
P95
Near historical high
vs 5Y Ago
30.1x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 557.81% |
| Q3 2025 | -82.56% |
| Q2 2025 | 719.82% |
| Q1 2025 | -88.90% |
| Q4 2024 | 16.26% |
| Q3 2024 | 611.17% |
| Q2 2024 | 29.19% |
| Q1 2024 | -87.11% |
| Q4 2023 | -0.72% |
| Q3 2023 | 13.02% |
| Q2 2023 | 47.11% |
| Q1 2023 | -44.83% |
| Q4 2022 | 25.69% |
| Q3 2022 | 29.25% |
| Q2 2022 | 49.22% |
| Q1 2022 | -19.09% |
| Q4 2021 | 13.38% |
| Q3 2021 | 17.14% |
| Q2 2021 | 24.73% |
| Q1 2021 | -22.65% |
| Q4 2020 | 18.56% |
| Q3 2020 | -68.37% |
| Q2 2020 | 511.10% |
| Q1 2020 | -69.88% |
| Q4 2019 | 184.78% |
| Q3 2019 | 34.36% |
| Q2 2019 | 30.95% |
| Q1 2019 | -52.18% |
| Q4 2018 | 106.46% |
| Q3 2018 | 17.45% |
| Q2 2018 | -25.16% |
| Q1 2018 | -33.09% |
| Q4 2017 | 214.69% |
| Q3 2017 | -58.18% |
| Q2 2017 | 208.38% |
| Q1 2017 | -72.96% |
| Q4 2016 | 154.33% |
| Q3 2016 | 3.06% |
| Q2 2016 | 107.92% |
| Q1 2016 | -70.39% |